KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6
Phase 1Recruiting 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed or Refractory Acute Myeloid Leukemia
Conditions
Relapsed or Refractory Acute Myeloid Leukemia
Trial Timeline
Oct 10, 2024 → Apr 30, 2028
NCT ID
NCT06812104About KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6
KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6 is a phase 1 stage product being developed by Kyowa Kirin for Relapsed or Refractory Acute Myeloid Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06812104. Target conditions include Relapsed or Refractory Acute Myeloid Leukemia.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed or Refractory Acute Myeloid Leukemia were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06812104 | Phase 1 | Recruiting |
Competing Products
20 competing products in Relapsed or Refractory Acute Myeloid Leukemia